$EYPT News

EyePoint: DURAVYU's Durability Could Drive Significant Upside

EyePoint (EYPT) Q1 2026 Earnings Transcript

RBC Capital Maintains Outperform on EyePoint, Lowers Price Target to $37

EyePoint Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary

EyePoint, Inc. (EYPT) Q1 2026 Earnings Call Transcript

Eyepoint Pharmaceuticals Q1 Earnings Call Highlights

EyePoint (EYPT) Reports Q1 Loss, Tops Revenue Estimates

EyePoint Inc. (NASDAQ:EYPT) Revenue Beats Estimates, Earnings Miss in Q1 2026 Report

Is It Time To Reassess EyePoint (EYPT) After A 120% One Year Share Price Surge

EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments

How The EyePoint (EYPT) Story Is Shifting With DURAVYU And Phase 3 DME Trials

EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?

EyePoint Pharmaceuticals Teases August Phase 3 Wet AMD Data for DURAVYU at RBC Ophthalmology Conference

How The EyePoint (EYPT) Story Is Shifting With Phase 3 DME And Duravyu In Focus

Citigroup Maintains Buy on EyePoint, Raises Price Target to $35

HC Wainwright & Co. Maintains Buy on EyePoint, Raises Price Target to $30

EyePoint: The 'Pre-Readout' Surge Is Hiding A Commercial Reality Check

EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript